These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The MPTP model of Parkinson's disease. Smeyne RJ; Jackson-Lewis V Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530 [TBL] [Abstract][Full Text] [Related]
6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
7. Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies. Olson L; Backlund EO; Gerhardt G; Hoffer B; Lindvall O; Rose G; Seiger A; Strömberg I Adv Neurol; 1987; 45():85-94. PubMed ID: 3030073 [No Abstract] [Full Text] [Related]
8. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? Poirier J; Thiffault C Eur Neurol; 1993; 33 Suppl 1():38-43. PubMed ID: 8375431 [TBL] [Abstract][Full Text] [Related]
9. The possible role of iron in the etiopathology of Parkinson's disease. Youdim MB; Ben-Shachar D; Riederer P Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792 [TBL] [Abstract][Full Text] [Related]
10. The visual system in Parkinson's disease. Bodis-Wollner I; Tagliati M Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159 [No Abstract] [Full Text] [Related]
11. Thirty years of dopamine research. Carlsson A Adv Neurol; 1993; 60():1-10. PubMed ID: 8093570 [No Abstract] [Full Text] [Related]
12. [Aging and Parkinson's disease]. Tohgi H; Abe T; Takahashi S No To Shinkei; 1991 Aug; 43(8):713-9. PubMed ID: 1931254 [No Abstract] [Full Text] [Related]
13. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. Youdim MB; Ben-Shachar D; Eshel G; Finberg JP; Riederer P Adv Neurol; 1993; 60():259-66. PubMed ID: 8380520 [No Abstract] [Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model. Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369 [TBL] [Abstract][Full Text] [Related]
15. Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans. Kopin IJ; Bankiewicz KS; Plunkett RJ; Jacobowitz DM; Oldfield EH Adv Neurol; 1993; 60():707-14. PubMed ID: 8420215 [No Abstract] [Full Text] [Related]
18. Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease. Tsang F; Soong TW IUBMB Life; 2003 Jun; 55(6):323-7. PubMed ID: 12938734 [TBL] [Abstract][Full Text] [Related]
19. [Parkinson's disease; etiology and animal model]. Mizuno Y No To Shinkei; 1991 Aug; 43(8):703-11. PubMed ID: 1931253 [No Abstract] [Full Text] [Related]
20. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]